The North America Osteoporosis Drugs Market would witness market growth of 3.7% CAGR during the forecast period (2020-2026). Osteoporosis is the degradation of bones owing to reduced bone density resulting in micro-architectural loss of bone tissue and a greater chance of fracture. This usually occurs at an older age, and women are more vulnerable to it than males by around three or four times. The World Health Organization reports that about 1.66 million hip fractures occur worldwide per year owing to osteoporosis. According to the National Osteoporosis Foundation, about 54 million Americans suffer from osteoporosis. The disease also has a genetic bias in that it affects more Caucasians than Asians. The incidence of the disease is lowest in the African community.
Osteoporosis is induced by low bone mass and tissue degradation, which raises the likelihood of fracture, especially in the spine and wrists. Providers depend on the development of more focused approaches, such as anabolic medications, for successful treatment of the disease. Anabolic agents promote new bone growth, enhance bone density, and increase bone mass, as well as reduce fracture incidence.
The anabolic agent developed by Radium Health Inc for the treatment of osteoporosis in postmenopausal women and the anabolic agent developed for the treatment of osteoporosis associated with prolonged systemic glucocorticoid therapy have also been licensed by the US FDA companies such as Amgen Inc and Astellas Pharma Inc. are now working on producing a bone-forming monoclonal antibody for the treatment medicament. In addition to product approvals, the existence of a promising medication pipeline for osteoporosis should improve the demand for osteoporosis medicines over the coming years.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: Osteoporosis Drugs Market in North America is expected to register a CAGR of 3.7% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the North America Osteoporosis Drugs Market Analysis
Market Segmentation:
By Route of Administration
- Oral
- Injectable and
- Other Route of Administration
By Drug Class
- Bisphosphonates
- Rank Ligand Inhibitors
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors Modulator (SERM) and
- Other Drug Classes
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Amgen, Inc.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Allergan PLC
- Eli Lilly and Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Osteoporosis Drugs Market, by Route of Administration
1.4.2 North America Osteoporosis Drugs Market, by Drug Class
1.4.3 North America Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Osteoporosis Drugs Market by Route of Administration
3.1 North America Oral Market by Country
3.2 North America Injectable Market by Country
3.3 North America Other Route of Administration Market by Country
Chapter 4. North America Osteoporosis Drugs Market by Drug Class
4.1 North America Bisphosphonates Market by Country
4.2 North America Rank Ligand Inhibitors Market by Country
4.3 North America Parathyroid Hormone Therapy Market by Country
4.4 North America Calcitonin Market by Country
4.5 North America Other Drug Class Market by Country
Chapter 5. North America Osteoporosis Drugs Market by Country
5.1 US Osteoporosis Drugs Market
5.1.1 US Osteoporosis Drugs Market by Route of Administration
5.1.2 US Osteoporosis Drugs Market by Drug Class
5.2 Canada Osteoporosis Drugs Market
5.2.1 Canada Osteoporosis Drugs Market by Route of Administration
5.2.2 Canada Osteoporosis Drugs Market by Drug Class
5.3 Mexico Osteoporosis Drugs Market
5.3.1 Mexico Osteoporosis Drugs Market by Route of Administration
5.3.2 Mexico Osteoporosis Drugs Market by Drug Class
5.4 Rest of North America Osteoporosis Drugs Market
5.4.1 Rest of North America Osteoporosis Drugs Market by Route of Administration
5.4.2 Rest of North America Osteoporosis Drugs Market by Drug Class
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 North America Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 2 North America Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 3 North America Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 4 North America Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 5 North America Oral Market by Country, 2016 - 2019, USD Million
TABLE 6 North America Oral Market by Country, 2020 - 2026, USD Million
TABLE 7 North America Injectable Market by Country, 2016 - 2019, USD Million
TABLE 8 North America Injectable Market by Country, 2020 - 2026, USD Million
TABLE 9 North America Other Route of Administration Market by Country, 2016 - 2019, USD Million
TABLE 10 North America Other Route of Administration Market by Country, 2020 - 2026, USD Million
TABLE 11 North America Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 12 North America Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 13 North America Bisphosphonates Market by Country, 2016 - 2019, USD Million
TABLE 14 North America Bisphosphonates Market by Country, 2020 - 2026, USD Million
TABLE 15 North America Rank Ligand Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 16 North America Rank Ligand Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 17 North America Parathyroid Hormone Therapy Market by Country, 2016 - 2019, USD Million
TABLE 18 North America Parathyroid Hormone Therapy Market by Country, 2020 - 2026, USD Million
TABLE 19 North America Calcitonin Market by Country, 2016 - 2019, USD Million
TABLE 20 North America Calcitonin Market by Country, 2020 - 2026, USD Million
TABLE 21 North America Other Drug Class Market by Country, 2016 - 2019, USD Million
TABLE 22 North America Other Drug Class Market by Country, 2020 - 2026, USD Million
TABLE 23 North America Osteoporosis Drugs Market by Country, 2016 - 2019, USD Million
TABLE 24 North America Osteoporosis Drugs Market by Country, 2020 - 2026, USD Million
TABLE 25 US Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 26 US Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 27 US Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 28 US Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 29 US Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 30 US Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 31 Canada Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 32 Canada Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 33 Canada Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 34 Canada Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 35 Canada Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 36 Canada Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 37 Mexico Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 38 Mexico Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 39 Mexico Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 40 Mexico Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 41 Mexico Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 42 Rest of North America Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 43 Rest of North America Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 44 Rest of North America Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 45 Rest of North America Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 46 Rest of North America Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 47 Rest of North America Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 48 Key Information – Amgen, Inc.
TABLE 49 key information – F. Hoffmann-La Roche Ltd.
TABLE 50 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 51 key information - Merck & Co., Inc.
TABLE 52 Key Information – Novartis AG
TABLE 53 Key Information – Pfizer, Inc.
TABLE 54 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 55 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 56 Key Information – Allergan PLC
TABLE 57 Key Information – Eli Lilly and Company
List of Figures
FIG 1 Methodology for the research